Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 490 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... June 5, 2023 Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers May 2, 2018 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... October 19, 2020 Shannen Doherty Reveals She Has Stage IV Breast Cancer February 5, 2020 Load more HOT NEWS Expanding the horizons of the life science economy VA Study Finds No Disparities in Prostate Cancer Deaths with Equal... EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced...
